The global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.
This report provide:
Download Report Overview
SCOPE OF THE STUDY
The scope of this study is testing, screening technology and also therapeutics markets for prostate cancer. The report also includes the regulatory environment, current technologies, new technologies, prostate cancer incidence, market projections and market share, along with latest trends and new developments.
ABOUT THE AUTHOR
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including IND enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.